Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07131475 · ClinicalTrials.gov registry record · Phase 2
Precision Biomarkers to Detect Brain Injury in Active-Duty United States Special Operations Forces With Repeated Blast Exposure
A Phase 2 study of Blast Injury, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT07131475 is a Phase 2 study of Blast Injury that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07131475, a Phase 2 study of Blast Injury, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 4-year, longitudinal study of 100 active-duty Navy SEALs. The goal of the study is to determine whether repeated blast exposure affects SEAL brain health and to develop an initial diagnostic testing protocol that detects repeated blast brain injury.
Conditions Studied
Interventions
- DRUG PBR28 TSPO PET
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-10-14 |
| Est. Completion | 2029-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07131475
The ClinicalTrials.gov registry entry for NCT07131475 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Blast Injury appearing as the primary indexed condition, and to 1 intervention - of which PBR28 TSPO PET is the first listed.
NCT07131475 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07131475 about?
NCT07131475 is a clinical study titled "Precision Biomarkers to Detect Brain Injury in Active-Duty United States Special Operations Forces With Repeated Blast Exposure". This is a 4-year, longitudinal study of 100 active-duty Navy SEALs. The goal of the study is to determine whether repeated blast exposure affects SEAL brain health and to develop an initial diagnostic testing protocol that detects repeated blast brain injury.
What is the current status of trial NCT07131475?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-10-14. Estimated completion is 2029-08-31.
What conditions does trial NCT07131475 study?
This clinical trial studies the following conditions: Blast Injury.
What interventions are being tested in trial NCT07131475?
The interventions under investigation include: PBR28 TSPO PET (DRUG).
Who is sponsoring clinical trial NCT07131475?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07131475 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.